Modernatx, Inc.
Clinical trials sponsored by Modernatx, Inc., explained in plain language.
-
New COVID shots tested in 30,000 adults to stop symptomatic illness
⭐️ VACCINE ⭐️ OngoingThis study tests two updated mRNA COVID-19 vaccines (mRNA-1283 and mRNA-1273 variant formulation) in 30,000 healthy adults aged 50 to 64 who are not at high risk for severe COVID-19. The goal is to see if these vaccines prevent symptomatic COVID-19 compared to a placebo. Research…
Phase: PHASE4 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 17, 2026 01:30 UTC
-
Could this mRNA shot stop the virus behind mono and cancer?
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests an experimental mRNA vaccine (mRNA-1195) designed to prevent Epstein-Barr virus (EBV) infection. About 482 healthy adults aged 18 to 55 will receive either the vaccine or a placebo. Researchers will monitor safety and measure the body's immune respons…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 15, 2026 19:06 UTC
-
Could this mRNA vaccine stop the virus behind mono and certain cancers?
⭐️ VACCINE ⭐️ OngoingThis study is testing an experimental mRNA vaccine called mRNA-1189 to see if it can safely prevent Epstein-Barr virus (EBV) infection in healthy people aged 10 to 30. EBV is a common virus that can cause mononucleosis and has been linked to some cancers. The vaccine is given as …
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 15, 2026 19:02 UTC
-
New mRNA shots aim to protect babies from two dangerous viruses
⭐️ VACCINE ⭐️ OngoingThis study tests two experimental mRNA vaccines in infants aged 5 to 24 months. One vaccine targets RSV alone, and the other targets both RSV and hMPV. The main goal is to see if the vaccines are safe and produce a strong immune response. Around 186 healthy infants will take part…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 12, 2026 12:04 UTC
-
Massive trial launches for first mRNA norovirus vaccine – could end winter vomiting bug
⭐️ VACCINE ⭐️ OngoingThis study tests an experimental mRNA vaccine (mRNA-1403) to prevent norovirus, a highly contagious virus that causes severe vomiting and diarrhea. About 38,000 adults aged 18 and older will receive either the vaccine or a placebo to see if it safely prevents moderate to severe s…
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 11, 2026 12:09 UTC
-
Could mRNA vaccines finally stop the stomach bug?
⭐️ VACCINE ⭐️ OngoingThis study tests two experimental mRNA vaccines (mRNA-1403 and mRNA-1405) to prevent norovirus, a highly contagious virus that causes vomiting and diarrhea. About 1,400 healthy adults aged 18 to 80 will receive either a vaccine or a placebo to check safety and how well the vaccin…
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 08, 2026 13:10 UTC
-
New mRNA vaccine aims to shield transplant patients from dangerous virus
⭐️ VACCINE ⭐️ OngoingThis study tests an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. About 84 participants will receive either the vaccine or a placebo. The goal is to see if the vaccine can safely prevent CMV after stopping stand…
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 02, 2026 11:39 UTC
-
MRNA therapy aims to control rare metabolic disease
Disease control OngoingThis early-stage trial tests an mRNA medicine called mRNA-3745 in 15 adults and children with glycogen storage disease type 1a (GSD1a), a rare condition where the body cannot properly release stored sugar. The main goal is to check safety and how well the drug controls blood suga…
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 17, 2026 01:41 UTC
-
Personalized mRNA vaccine shows promise in stopping melanoma recurrence
Disease control OngoingThis study tests whether adding a personalized cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from returning after surgery compared to pembrolizumab alone. About 267 people with high-risk melanoma that has spread to lymph nodes and …
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
MRNA cancer shots tested in 42 patients with advanced tumors
Disease control OngoingThis early-stage study tests two experimental mRNA treatments (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors that have not responded to standard therapy. The goal is to check safety and tolerability, with mRNA-4200 given alongside a checkpoint inhibitor. This i…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 01, 2026 18:05 UTC
-
Healthy volunteers needed to test new mRNA drug safety
Knowledge-focused OngoingThis early-stage study tests whether the experimental drug mRNA-0184 is safe in healthy adults. About 52 participants will receive one or more doses and be monitored for side effects. The study does not aim to treat any disease, but to gather important safety and drug-level infor…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Knowledge-focused
Last updated Jun 17, 2026 01:42 UTC
-
Thousands monitored for vaccine side effects in korean safety study
Knowledge-focused OngoingThis study tracks over 4,200 people in South Korea who received a SPIKEVAX COVID-19 vaccine to see if any side effects occur over time. Participants are aged 12 or older depending on the vaccine version. The goal is to gather real-world safety data, not to test if the vaccine wor…
Sponsor: ModernaTX, Inc. • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:12 UTC